Category: Europe

November 5, 2015 Off

Verona Pharma completes inhibitor study

By Dino Mustafić

Verona Pharma has completed patient enrolment for the Phase IIa dose-finding study of RPL554 in asthma and the Phase IIa combination study of RPL554 in chronic obstructive pulmonary disease (COPD), in which the drug is being administered in addition to standard of care bronchodilators.